The abbreviations used are: CHO, Chinese hamster ovary; CRD, cysteine-rich domain; EGFR, epidermal growth factor receptor; FGF, fibroblasts growth factor; HA, hemagglutinin; IB, immunoblotting; IP, immunoprecipitation; MAPK, mitogenactivated protein kinase; RNAi, RNA interference; RTK, receptor tyrosine kinase; SH2, Src-homology 2; SRE, serum response element; Spry2, Sprouty-2. These results attribute a novel role for carboxyl-terminal tyrosine residues and yet unidentified phosphotyrosine-binding proteins in the differential regulation of Sprouty-2 activity.
Introduction
RTKs play pivotal roles in morphogenesis, cell fate determination and pathogenesis.
Signaling initiated upon binding of growth factors to their cognate RTKs is under stringent regulation. Negatively acting pathways operate at multiple sites downstream to the receptor, as well as on the level of the stimulating receptor itself [reviewed in C. Rubin et al., page 4 activation, c-Cbl binds phosphorylated Spry2 through its SH2 domain (10, 11, 26) .
This association results in the ubiquitylation and proteasomal degradation of active Spry2 molecules. In parallel, this type of association enables Spry2 to sequester c-Cbl.
Since c-Cbl drives the ubiquitylation and degradation of the activated form of EGFR (27) (28) (29) (30) , its sequestration is thought to enhance receptor activity and downstream signaling.
Mammalian Sprouty proteins have clearly retained the ability to inhibit MAPK activation by FGF, however their effects on EGF-induced activation of the MAPK pathway are less understood. It has been proposed that the carboxyl terminal half of Spry2 inhibits EGF-induced signaling to the MAPK pathway, but the full-length protein enhances EGF-induced MAPK signals (14) . Others have suggested that Spry2 as well as Spry4 can inhibit EGF-induced MAPK activation possibly through interactions with the Grb2 adaptor protein (5, 31) . The evidence we present indicates that Spry2 regulates FGFR and EGFR through distinct mechanisms. While both pathways induce phosphorylation of the amino-terminally localized tyrosine 55, only the FGF pathway can induce significant phosphorylation of tyrosines residing within the carboxyl-terminus of the protein. By employing Spry2 mutants and RNA interference, our studies propose that recruitment of phosphotyrosine-binding proteins other than Grb2, to the cysteine-rich domain of Spry2 underlies the disparate inhibitory action upon different RTKs.
Experimental Procedures
Materials-Unless indicated, materials were purchased from Sigma (St. Louis, MO).
A mutagenesis kit was purchased from Stratagene (Cedar Creek, TX). Antihemagglutinin (HA) rat monoclonal antibody 3F10 was purchased from Roche by guest on http://www.jbc.org/ Downloaded from C. Rubin et al., page 5 Molecular Biochemicals (Mannheim, Germany). For immunoblotting analysis of cSrc we used a monoclonal antibody purchased from Upstate Biotechnology (Lake Placid, NY). Antibodies against the N-and C-terminal regions of Spry2 were provided by Sigma Israel (Nes-Ziona, Israel). A monoclonal anti-phosphotyrosine antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Goat antirat peroxidase-conjugated IgG was purchased from Jackson ImmunoResearch (West Grove, PA). Peroxidase-conjugated protein A was from ICN (Costa Mesa, CA).
Cell culture, transfection and immunoprecipitation-COS7 and CHO cells were transfected by using the Lipofectamine method (Invitrogen, Carlsbad, CA). For HEK-293T cells we used the calcium-phosphate method. The total amount of DNA in each transfection was normalized with the pcDNA3 plasmid. Cells were assayed 48 hours after transfection. Cell lysis in solubilization buffer [50mM HEPES (pH 7.5), 150mM NaCl, 10% glycerol, 1% Triton X-100, 1mM EDTA, 1mM EGTA, 10mM NaF, 30mM -glycerol phosphate, 0.2mM Na 3 VO 4 and a protease inhibitor cocktail], immunoprecipitation and western blotting were carried out essentially as described (27) . For MAPK assays we used immunoblotting with antibodies to the active form, followed by re-blotting with antibodies to general Erk.
Immunofluorescence-CHO and COS7 cells were fixed for 15 min with 3% paraformaldehyde, and permeabilized for 10 min at 22°C with saline containing 1% albumin and either 0.2% Triton X-100 or 0.1% saponin, respectively . For labeling, cells were incubated for 1 hour at room temperature with an anti-HA monoclonal antibody. After extensive washing, cells were incubated for an additional hour with a Cy3-conjugated donkey anti-rat antibody. Subsequently, cover-slips were mounted in by guest on http://www.jbc.org/ Downloaded from C. Rubin et al., page 6 Mowiol (Calbiochem, San Diego, CA). Confocal microscopy was performed using a Zeiss 510 microscope.
SRE transcription assay-CHO cells co-transfected in triplicates with the indicated plasmids, along with a reporter pSRE-Fluc plasmid (1µg), which contains the serum response element (SRE) cloned upstream to the c-fos minimal promoter (nucleotides -53/+45) and the luciferase gene (32) . Twenty-four hours later, cells were treated with growth factors (20ng/ml) or left untreated for 12 hours. The luciferase reporter assay was performed by using a luciferase assay system with reporter lysis buffer (Promega, Madison, WI). The results were normalized to protein concentrations in whole cell extracts.
Construction of expression vectors-HA-tagged pCGN/Spry2 has been previously described (14) . Spry2 point mutants were generated by site-directed mutagenesis. Src expression vectors and the control pUSE vector were purchased from Upstate Biotechnology (Lake Placid, NY). The pSUPER RNAi expression vector was provided by Reuven Agami (NKI, Amsterdam). Two gene-specific inserts specifying 19-nucleotide sequences corresponding to nucleotides 189-207 and 818-836 downstream of the Spry2 translation start site were cloned into the pSUPER vector as described (33) .
Results

Both FGF and EGF elevate Spry2 expression but subsequently FGF and not EGF
signaling is down regulated -Spry2 is a well-established negative feedback regulator of signals emanating from the FGFR, but the effect of Spry2 on EGFR signaling by guest on http://www.jbc.org/ Downloaded from C. Rubin et al., page 7 remains unclear [reviewed in (4) ]. To test whether Spry2 levels are altered upon activation of each receptor, we treated HEK-293T cells with FGF or EGF and examined the levels of endogenous Spry2 using a specific antibody. A marked increase in Spry2 expression was detectable already within an hour of stimulation with either growth factor (Fig. 1A) , thus confirming induction of Spry2 expression by the respective RTKs in HEK-293T cells.
Next, we asked whether the increased expression of Spry2 would inhibit signaling initiated by either growth factor. To this end, we ectopically expressed thereafter Spry2 expression levels were examined. Expression of endogenous Spry2 was almost completely eliminated by a combination of the Spry2-RNAi plasmids, confirming the effectiveness of this approach (Fig. 1D) . When MAPK signaling was tested in Spry2 knocked-down cells at time windows corresponding to maximal activation by each ligand, we found enhanced activation of Erk in response to FGF and a slightly decreased activation of Erk in response to EGF (Fig. 1E) . We attribute the accelerated down-regulation of MAPK signals in EGF-treated cells to the previously reported ability of Spry2 to sequester c-Cbl, thereby inhibiting EGFR endocytosis and prolonging MAPK signals (10, 11, 26) . In summary, although with either FGF or EGF leads to enhanced expression of Spry2, the gain-of-function and loss-of-function approaches we employed imply that the newly induced protein inhibits FGF-induced activation of Erk, while sparing (or slightly activating) MAPK signals downstream to EGFR.
Activation of FGFR but not EGFR induces Spry2 phosphorylation on carboxyl-
terminal tyrosine residues -Spry2 phosphorylation on an amino-terminal tyrosine residue (Tyr-55) is critical for its regulatory role towards the Ras-MAPK pathway [reviewed in (4) ]. This tyrosine becomes phosphorylated in response to activation of both EGFR and FGFR and it may serve as a docking site for signaling molecules such tyrosine-55, as well as carboxyl-terminal tyrosines (Fig. 2D ). Hence, we tested the possible involvement of c-Src in EGF-and FGF-induced modification of Spry2 using a dominant-negative mutant of c-Src (DN-Src), mutated at the ATP-binding lysine residue (Lys-297). DN-Src totally abolished Src-mediated phosphorylation of Spry2, but incompletely eliminated the tyrosine phosphorylated form of Spry2 from cells over-expressing either RTK (Fig. 2E) . Of note, phosphorylation of Spry2 upon EGFR activation is characteristically weaker than the modifications initiated by FGFR or Src. In conclusion, although Src is a primary regulator of Spry2, additional tyrosine kinases may link RTKs to Spry2. Regardless of Src involvement, these results raised the possibility that preferential modification of CRD-located tyrosines underlies the inhibitory action of Spry2 towards FGFR.
Carboxyl-terminal tyrosines of Spry2 are required for efficient signaling inhibition
but not for protein localization -To investigate the prediction that CRD tyrosines play an inhibitory role, we expressed the 6F-Spry2 mutant in HEK-293T cells. Wild type Spry2 significantly reduced Erk activation in response to FGF, but the 6F-Spry2 mutant lost the inhibitory activity (Fig. 3A, left panel) . Similarly, replacement of tyrosine-55 also abrogated the inhibitory activity of Spry2 (Fig. 3A, right panel) , in line with a necessity for modifications at both N-and C-terminal tyrosine residues. To confirm these results, we examined the ensuing FGF-induced activation of transcription from the SRE of the c-fos promoter. CHO cells were co-transfected with an SRE reporter plasmid, along with different Spry2 constructs. As expected, wild type but not 6F-or Y55F-Spry2 reduced FGF-induced transcription from the c-fos promoter (Fig. 3B) , in support of the proposed involvement of both amino-and carboxyl-terminal tyrosines in the inhibitory action of Spry2. 
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Spry2 is localized to cytoplasmic vesicles, as well as to the plasma membrane, and its translocation to membrane ruffles involves the CRD (6, 7) . Since all six carboxyl-terminal tyrosines are located within this region, we tested whether their mutation would impair Spry2 localization. Immunofluorescence and confocal microscopy confirmed the previously reported vesicular localization of wild type Spry2 in CHO cells (10, 11) , a distribution shared by the 6F-Spry2 mutant (Fig. 3C) , and analysis of COS7 cells revealed EGF-induced translocation of both forms of Spry2 to membrane ruffles (Fig. 3C) . Hence, the impaired ability of 6F-Spry2 to inhibit MAPK signaling may not be attributed to altered tertiary structure or to defective cellular localization.
In an attempt to identify individual carboxyl-terminal tyrosines necessary for inhibition of MAPK signaling by Spry2, we constructed a set of six tyrosine add-back mutants on the background of 6F-Spry2. The mutants were tested for possible restoration of the inhibitory capacity of Spry2 by measuring Erk activation upon FGF stimulation. This assay revealed that tyrosine-227 is more critical than other tyrosines for effective signaling inhibition. Three independent experiments were quantified (Fig. 4B) , of which Figure 4A is a representative example. Two lines of evidence support the notion that phosphorylation of tyrosine 227 occurs and it is necessary for inhibition of MAPK. First, unlike a tyrosine-less mutant, 7F-Spry2, which underwent no phosphorylation when co-expressed with FGFR, the respective add-back mutant, namely 7F/2227Y, underwent significant phosphorylation (Fig. 4C) . Second, mutagenesis of tyrosine 227 interfered with the inhibitory action of Spry2 (Fig. 4D) .
Notably, in addition to tyrosine-227, two other tyrosines, namely tyrosines 269 and 283, also contributed to the inhibitory activity of Spry2, albeit to a lesser extent, while the relatively low expression level of the 6F-283Y mutant may obscure its function. In (Fig. 3 ) might be due to lack of association with Grb2. Several tyrosine mutants of Spry2, including a mutant whose seven tyrosines were changed to phenylalanines (7F-Spry2), were used. Co-expression of Grb2 and Spry2 was sufficient for detection of physical complexes, which were enhanced by a coexpressed FGFR (Fig. 5A) . Likewise, Grb2-Spry2 complexes were detectable even in the absence of an ectopic EGFR, but overexpression of the receptor significantly enhanced the interactions between the two adaptors (Fig. 5B) . In both cases, examination of mutant Spry2 proteins, including the tyrosine-less 7F form, suggested that Grb2-Spry2 associations may not require tyrosine phosphorylation of Spry2.
Notably, introduction of Grb2 did not alter the effect of Spry2 on the state of Erk/MAPK activation (data not shown).
To test this conclusion, we used an SH2-defective Grb2 mutant (R86K), which cannot bind phosphorylated substrates. As expected, R86K-Grb2 and wild type Grb2 co-immunoprecipitated with Spry2 to a similar extent (Fig. 5C ). To corroborate these observations, we attempted reconstitution of Spry2-Grb2 interactions in a cell-free system devoid of tyrosine phosphorylation. Therefore, we utilized bacterially produced Spry2 (tagged with poly-histidine) and Grb2 (in the form of a GST fusion protein). Pull-down experiments using the two bacterially produced proteins indicated that Spry2 associates with wild type, as well as R86K Grb2, but the isolated SH2 domain of Grb2 retained no binding to Spry2 (Fig. 5D ). Taken together with other lines of evidence, these results exclude the involvement of phosphorylated tyrosine residues of Spry2 in binding to Grb2, in line with the notion that a phosphotyrosinebinding protein other than Grb2 is involved in the inhibitory action of Spry2.
Discussion
Various inhibitory mechanisms have evolved to control RTK signaling [reviewed in 
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Sprouty proteins have evolved as complex feedback regulators of RTKs, which impede MAPK activation by numerous transmembrane and other tyrosine kinases. Genetic studies indicated that dSpry, the founder of the Sprouty family, is a general inhibitor of RTKs. Surprisingly, several studies demonstrated that overexpression of mammalian Spry2 either augments or does not affect EGF signaling (6, 11, 13, 14) , while others claimed that Spry2 reduces EGF-mediated signaling (5,31). Alternatively, it has been suggested that the CRD of Spry2 inhibits EGF-mediated signaling, while the amino-terminus confers stimulatory activity (14) .
These discrepancies may stem from the use of ectopic expression systems that in some cases obscure elucidation of physiological outcomes. To address this question we utilized RNA interference to ablate Spry2 expression. Both loss-of-function ( (Fig. 2A) . In support of this notion, a recent study demonstrated that a Y55F mutant of Spry2 is phosphorylated in NIH-3T3 cells, albeit at low levels (36) .
To test a possible role for carboxyl-terminal phosphorylation sites, we constructed a mutant in which all carboxyl-terminal tyrosines were mutated to phenylalanines (6F-Spry2). This mutant retained its ability to undergo phosphorylation on tyrosine 55 (Figs. 2B and 2D ) and exhibited similar cellular localization and translocation to that of the wild type protein (Fig. 3C) . However, mutation of all carboxyl-terminal tyrosines impaired the ability of Spry2 to inhibit FGF-induced MAPK activation and transcription from the SRE (Figs. 3A and 3B ).
Tyrosine add-back mutants on the background of 6F-Spry2 indicated that tyrosine 227 is required for efficient inhibition of MAPK activation, and further experiments indicated that this residue is modified by FGFR (Fig. 4C) . Two other tyrosines, namely tyrosine 269 and 283, also contribute to the inhibitory activity of Spry2, although to a lesser extent. Thus, activation of the inhibitory capacity of Spry2 requires both amino-terminal (tyrosine 55), as well as carboxyl-terminal phosphorylation events. Conceivably, these phosphorylation sites serve as docking sites for phosphotyrosine-binding proteins that mediate the inhibitory effect of Spry2. 
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Alternatively, mutagenesis of carboxyl-terminal tyrosines may perturb the tertiary structure of the CRD. However, since the CRD mediates Spry2 localization (7, 41) , and the 6F mutant displayed normal distribution (Fig. 3C) , this may not be the case.
Several studies have reported an association between Spry2 and Grb2 (5,36).
It has been suggested that Spry2 may impede MAPK activation by sequestering Grb2, thereby disconnecting the receptor from downstream signaling components (5). Since the 6F-Spry2 mutant was inactive in inhibiting FGF-induced MAPK signaling, we tested if this effect could be explained by altered Grb2 binding. The 6F-Spry2 mutant, as well as a 7F mutant lacking all tyrosines, strongly associated with Grb2 (Figs. 5A and 5B). It is notable that tyrosine 55, which had been previously suggested to serve as a docking site for the SH2 domain of Grb2, does not conform to the Grb2 binding consensus (Tyr-Xxx-Asn) and our own data indicate that it is not required for Grb2 binding (Figs. 5A and 5B). Interestingly, Spry2-Grb2 associations were modestly enhanced by EGFR or FGFR activation as reported by some (5,16), but not other groups (34, 36) . A similar increase in association was observed even in the absence of all seven tyrosines of Spry2. Hence, it is likely that the induction of association between Spry2 and Grb2 is due to cellular translocation events rather than the induction of Spry2 tyrosine phosphorylation. Indeed, a phosphorylation-independent mechanism of association was supported by the ability of an SH2-defective Grb2 mutant to bind Spry2 (Fig. 5C) . Finally, in-vitro association between bacterially produced Grb2 and Spry2 demonstrated that the single SH2 domain of Grb2 may not be necessary for Spry2 binding (Fig. 5D) . 
